The global orthopedic devices market is projected to grow from USD 44.09 billion in 2023 to USD 57.79 billion by 2030 at a compound annual growth rate (CAGR) of 4.78%, driven by rising musculoskeletal disorders, demographic aging, and technological innovation. Key players such as Stryker, Zimmer Biomet, Johnson & Johnson, Medtronic, Maxx Orthopedics, Hyalex Orthopaedics, and OrthoPreserve are advancing through FDA approvals, breakthrough device designations, and the integration of AI in devices like the UNID spinal fusion system. Notable regulatory milestones include FDA clearances for Maxx Orthopedics' Freedom® Total Knee System in June 2025, Hyalex Orthopaedics' Freestyle Knee Implant in May 2025, and the SetPoint System for rheumatoid arthritis in August 2025. Johnson & Johnson MedTech showcased major advances at the AAOS 2025 Annual Meeting in March 2025, and OrthoPreserve received Breakthrough Device Designation in January 2025. Market dynamics are shaped by aging populations, increasing prevalence of osteoarthritis and rheumatoid arthritis, and innovations in implant materials, AI-enabled devices, and minimally invasive surgical tools.

Stryker Corporation, a leading medical technology company with a $144.88 billion market capitalization, reported strong financial performance in Q2 2025, with 11.36% revenue growth to $23.82 billion and improved gross and operating margins. The company expanded its portfolio through the acquisition of Inari Medical in early 2025, enhancing its presence in the venous thromboembolism (VTE) market, while divesting its Spinal Implants business to Viscogliosi Brothers LLC to form VB Spine, LLC. Stryker maintains leadership in robotic surgery via its Mako system, with record installations and upcoming product launches. Despite challenges such as tariff impacts (now estimated at $175 million) and short-term earnings dilution from acquisitions, the company has raised revenue and earnings guidance to 8.5–9.5% organic growth. Analysts project double-digit growth in 2025, supported by a strong order backlog and a history of consistent dividend payments. The company’s strategic focus on high-growth segments and innovation positions it well for future success.

The Smart Infusion System Market is projected to grow from USD 6.42 billion in 2024 to USD 13.14 billion by 2032, reflecting a CAGR of 9.37% from 2025 to 2032. Driven by technological innovation, rising chronic disease prevalence, and a focus on patient safety, the market is expanding across hospitals, clinics, and home healthcare settings. Key segments include oncology, pain management, and critical care, with growth fueled by wireless connectivity, AI-driven dose calculation, and multi-fluid compatibility. The market is segmented geographically by region, with North America leading, followed by Europe and Asia-Pacific, which is the fastest-growing region. Major players such as Zoll Medical, Medtronic, and Abbott Laboratories are investing in advanced technologies, safety features, and strategic partnerships to maintain competitive advantage. The industry is expected to see increased mergers, acquisitions, and collaborations, with a strong emphasis on regulatory compliance and innovation in AI and wearable devices.

DelveInsight's market report analyzes the global occlusion devices market, projecting a compound annual growth rate (CAGR) of 6.31% from 2024 to 2030. The growth is driven by rising prevalence of chronic conditions, increasing demand for minimally invasive surgeries, favorable reimbursement policies, and an expanding geriatric population. Key factors include cardiovascular diseases, cancer, and neurological conditions like brain aneurysms. North America is projected to hold the largest market share in 2023. The report highlights recent product launches such as Front Line Medical Technologies' COBRA-OS, Terumo Medical Corporation's AZUR Vascular Plug, and Boston Scientific's WATCHMAN FLX, as well as the impact of the COVID-19 pandemic on treatment delays. It covers market segments by product type, end user, and geography, and includes key players such as Abbott, Terumo, Edwards Lifesciences, Boston Scientific, and others.

The Medical Design & Outsourcing Medtech Big 100 ranking reveals a stagnation in R&D spending growth among the world’s largest medical device companies, following years of double-digit increases. Factors include rising material costs due to import taxes, potential U.S. recession risks, and federal funding cuts. While some companies like Johnson & Johnson MedTech and Stryker increased R&D investments, others like Medtronic and Siemens Healthineers reported declines. The slowdown raises concerns about future innovation and patient outcomes, with experts predicting increased M&A activity as companies seek external innovations.